Influenza A virus and its antiviral drug treatment options

[1]  Bin Zhou,et al.  Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. , 2021, The Lancet. Infectious diseases.

[2]  Hao Tan,et al.  Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with in vivo antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses , 2021, Emerging microbes & infections.

[3]  Ying Kong,et al.  Gut microecology: Why our microbes could be key to our health. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  Malobika Chakravarty,et al.  Nanotechnology-based antiviral therapeutics , 2020, Drug Delivery and Translational Research.

[5]  M. Shirley.  Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza , 2020, Drugs.

[6]  Heung Kyu Lee,et al.  Host Protective Immune Responses against Influenza A Virus Infection , 2020, Viruses.

[7]  Chunlong Ma,et al.  Investigation of the Drug Resistance Mechanism of M2-S31N Channel Blockers through Biomolecular Simulations and Viral Passage Experiments. , 2020, ACS pharmacology & translational science.

[8]  Jun Wang,et al.  Put a cork in it: Plugging the M2 viral ion channel to sink influenza , 2020, Antiviral Research.

[9]  E. Takashita.  Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance. , 2020, Cold Spring Harbor perspectives in medicine.

[10]  Yimin Li,et al.  Efficacy of convalescent plasma for the treatment of severe influenza , 2020, Critical Care.

[11]  D. Botezat,et al.  Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers , 2020, Pharmaceutics.

[12]  Chunlong Ma,et al.  Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26I and M2-S31N/V27A from the influenza A viruses. , 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  Jun Wang,et al.  Focusing on the influenza virus polymerase complex: recent progress in drug discovery and assay development. , 2019, Current medicinal chemistry.

[14]  Yun Zhang,et al.  Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus , 2019, Viruses.

[15]  D. Baker.  Baloxavir marboxil , 2019, Reactions Weekly.

[16]  M. Shaw,et al.  Baloxavir marboxil: the new influenza drug on the market. , 2019, Current opinion in virology.

[17]  F. Hayden,et al.  Influenza virus polymerase inhibitors in clinical development , 2019, Current opinion in infectious diseases.

[18]  Asher Mullard.  FDA approves first new flu drug in 20 years , 2018, Nature Reviews Drug Discovery.

[19]  Shile Huang,et al.  Host Immune Response to Influenza A Virus Infection , 2018, Front. Immunol..

[20]  Larance Ronsard,et al.  The emerging influenza virus threat: status and new prospects for its therapy and control , 2018, Archives of Virology.

[21]  Maxim N. Artyomov,et al.  The microbial metabolite desaminotyrosine protects from influenza through type I interferon , 2017, Science.

[22]  Thavendran Govender,et al.  The role of nanotechnology in the treatment of viral infections , 2017, Therapeutic advances in infectious disease.

[23]  W. DeGrado,et al.  An M2‐V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine‐sensitive and ‐resistant influenza A viruses , 2017, Antiviral research.

[24]  I. Wilson,et al.  Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol , 2016, Proceedings of the National Academy of Sciences.

[25]  L. Naesens,et al.  Antiviral therapies on the horizon for influenza. , 2016, Current opinion in pharmacology.

[26]  F. Li,et al.  Inhibitors targeting the influenza virus hemagglutinin. , 2015, Current medicinal chemistry.

[27]  Kai Ludwig,et al.  Receptor binding and pH stability - how influenza A virus hemagglutinin affects host-specific virus infection. , 2014, Biochimica et biophysica acta.

[28]  Shuwen Liu,et al.  Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin , 2013, Viruses.

[29]  Fei Zhao,et al.  Recent Advances in Neuraminidase Inhibitor Development as Anti‐influenza Drugs , 2012, ChemMedChem.

[30]  R. Webby,et al.  Structural and Biochemical Basis for Development of Influenza Virus Inhibitors Targeting the PA Endonuclease , 2012, PLoS pathogens.

[31]  A. Boylston.  The origins of inoculation , 2012, Journal of the Royal Society of Medicine.

[32]  M. Okun,et al.  Amantadine , 2012, Neurology.

[33]  T. Noda.  Native Morphology of Influenza Virions , 2012, Front. Microbio..

[34]  G. Air.  Influenza neuraminidase , 2011, Influenza and other respiratory viruses.

[35]  S. Cinti,et al.  Peramivir: A New Drug for Influenza , 2011 .

[36]  R. Webster,et al.  Drugs in Development for Influenza , 2010, Drugs.

[37]  B. Davies,et al.  Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations , 2010, The Journal of antimicrobial chemotherapy.

[38]  J. Leider,et al.  Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? , 2010, Transfusion.

[39]  Nelson A. Ochekpe,et al.  Nanotechnology and Drug Delivery Part 2: Nanostructures for Drug Delivery , 2009 .

[40]  Rajesh Singh,et al.  Nanoparticle-based targeted drug delivery. , 2009, Experimental and molecular pathology.

[41]  Nicole M. Bouvier,et al.  The biology of influenza viruses. , 2008, Vaccine.

[42]  S. Grabar,et al.  Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals. , 2008, Vaccine.

[43]  Shashi K Murthy,et al.  Nanoparticles in modern medicine: State of the art and future challenges , 2007, International journal of nanomedicine.

[44]  W. Barclay,et al.  Infection of Human Airway Epithelium by Human and Avian Strains of Influenza A Virus , 2006, Journal of Virology.

[45]  D. Pérez,et al.  Quail carry sialic acid receptors compatible with binding of avian and human influenza viruses. , 2006, Virology.

[46]  C. Mayer.  Nanocapsules as Drug Delivery Systems , 2005, The International journal of artificial organs.

[47]  A. Moscona.  Neuraminidase inhibitors for influenza. , 2005, The New England journal of medicine.

[48]  Yasuo Suzuki,et al.  Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. , 2005, Biological & pharmaceutical bulletin.

[49]  J. Buckner,et al.  Optimization of Human T-Cell Expansion Ex Vivo Using Magnetic Beads Conjugated with Anti-CD3 and Anti-CD28 Antibodies , 2004, Journal of immunotherapy.

[50]  Alok K. Chakrabarti,et al.  Role of Transmembrane Domain and Cytoplasmic Tail Amino Acid Sequences of Influenza A Virus Neuraminidase in Raft Association and Virus Budding , 2004, Journal of Virology.

[51]  A. García-Sastre,et al.  Reverse genetics studies on the filamentous morphology of influenza A virus. , 2003, The Journal of general virology.

[52]  G. Stiver.  The treatment of influenza with antiviral drugs. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[53]  H. Klenk,et al.  Functional balance between haemagglutinin and neuraminidase in influenza virus infections , 2002, Reviews in medical virology.

[54]  Ayub Ali,et al.  Transport of viral proteins to the apical membranes and interaction of matrix protein with glycoproteins in the assembly of influenza viruses. , 2001, Virus research.

[55]  J. V. Ashley,et al.  Updated treatment for influenza A and B. , 2000, American family physician.

[56]  J. Gerber.  Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  P. Ward,et al.  Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802 , 1999, Clinical pharmacokinetics.

[58]  D. Steinhauer,et al.  Role of hemagglutinin cleavage for the pathogenicity of influenza virus. , 1999, Virology.

[59]  G. Blobel,et al.  Nuclear Import of Influenza Virus RNA Can Be Mediated by Viral Nucleoprotein and Transport Factors Required for Protein Import (*) , 1995, The Journal of Biological Chemistry.

[60]  M. Nahata,et al.  Rimantadine: A Clinical Perspective , 1995, The Annals of pharmacotherapy.

[61]  C. Miller.  New Rx for influenza A: flumadine. , 1994, Geriatric nursing.

[62]  C. Benham,et al.  An influenza virus containing nine different RNA segments. , 1991, Virology.

[63]  P. Grimont,et al.  Clostridium orbiscindens sp. nov., a human intestinal bacterium capable of cleaving the flavonoid C-ring. , 1991, International journal of systematic bacteriology.

[64]  J. Skehel,et al.  The molecular basis of the specific anti‐influenza action of amantadine. , 1985, The EMBO journal.

[65]  R. Krug,et al.  Influenza virus, an RNA virus, synthesizes its messenger RNA in the nucleus of infected cells , 1981, Cell.

[66]  G. Shearer,et al.  Human cytotoxic T cell responses to trinitrophenyl hapten and influenza virus. Diversity of restriction antigens and specificity of HLA-linked genetic regulation. , 1980, The Journal of experimental medicine.

[67]  A. Isaacs,et al.  Counts of influenza virus particles. , 1954, Journal of general microbiology.

[68]  K. Ng.  Xofluza (Baloxavir Marboxil) for the Treatment Of Acute Uncomplicated Influenza. , 2019, P & T : a peer-reviewed journal for formulary management.

[69]  Jeremy C. Jones,et al.  Influenza vaccines: the good, the bad, and the eggs. , 2010, Advances in virus research.

[70]  H. Oshitani,et al.  Emergence of amantadine-resistant influenza A viruses: epidemiological study , 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[71]  S. Cloarec,et al.  Influenza Diagnosis and Treatment , 2003, Clinical drug investigation.

[72]  F. Aoki,et al.  Clinical Pharmacokinetics of Amantadine Hydrochloride , 1988, Clinical pharmacokinetics.